X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
INDRAPRASTHA MEDICAL Fact Sheet, INDRAPRASTHA MEDICAL Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDRAPRASTHA MEDICAL Fact Sheet   (IRMED)

Here is the latest financial fact sheet of INDRAPRASTHA MEDICAL. For more details, see the INDRAPRASTHA MEDICAL quarterly results and INDRAPRASTHA MEDICAL share price and chart. For a sector overview, read our pharmaceuticals sector report.

INDRAPRASTHA MEDICAL Price History

Price Rs 53.8
Mkt Cap Rs m 4,932
Vol '000 15.7
P/E X 17.7
P/CF X 7.8
EPS (TTM) Rs 3.0
% ch % -1.3
No. of shares m 91.67
% ch week % -6.5
% ch 1-mth % -5.6
% ch 12-mth % -3.5
52 week H/L Rs 68.4/45.4
(As on Feb 21, 2018 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

INDRAPRASTHA MEDICAL Financials

No. of Mths
Year Ending
12
Mar-10
12
Mar-11
12
Mar-12
12
Mar-13
12
Mar-14
5-Yr Chart
Click to enlarge
INDRAPRASTHA MEDICAL EQUITY SHARE DATA
High Rs5453444241 
Low Rs2830313229 
Sales per share (Unadj.) Rs46.347.554.964.572.0 
Earnings per share (Unadj.) Rs3.43.42.93.13.9 
Diluted earnings per shareRs3.43.42.93.13.9 
Cash flow per share (Unadj.) Rs5.55.75.36.06.9 
Dividends per share (Unadj.) Rs1.601.601.601.601.80 
Adj. dividends per shareRs1.601.601.601.601.80 
Dividend yield (eoy) %3.93.94.34.35.1 
Book value per share (Unadj.) Rs14.816.317.418.720.4 
Adj. book value per shareRs14.816.317.418.720.4 
Shares outstanding (eoy) m91.6791.6791.6791.6791.67 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x0.90.90.70.60.5 
Avg P/E ratio x12.112.412.711.99.1 
P/CF ratio (eoy) x7.57.37.06.35.1 
Price / Book Value ratio x2.82.52.22.01.7 
Dividend payout %47.247.754.351.046.6 
Avg Mkt Cap Rs m3,7583,8043,4383,4283,222 
No. of employees `0002.93.02.93.23.1 
Total wages/salary Rs m8249851,1781,2661,418 
Avg. sales/employee Rs Th1,444.11,430.61,739.21,871.02,125.7 
Avg. wages/employee Rs Th280.5323.7407.3400.6456.6 
Avg. net profit/employee Rs Th105.7101.093.491.0114.1 
INDRAPRASTHA MEDICAL INCOME DATA
Net Sales Rs m4,2444,3555,0305,9126,600 
Other income Rs m121269197169186 
Total revenues Rs m4,3654,6245,2266,0826,786 
Gross profit Rs m576434481631733 
Depreciation Rs m193216218259281 
Interest Rs m3944598696 
Profit before tax Rs m466443400455542 
Minority Interest Rs m00000 
Prior Period Items Rs m09000 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m155145130167187 
Profit after tax Rs m311307270288354 
Gross profit margin %13.610.09.610.711.1 
Effective tax rate %33.332.832.536.834.6 
Net profit margin %7.37.15.44.95.4 
INDRAPRASTHA MEDICAL BALANCE SHEET DATA
Current assets Rs m9079501,1941,3201,473 
Current liabilities Rs m1,3191,2821,7631,9621,920 
Net working cap to sales %-9.7-7.6-11.3-10.9-6.8 
Current ratio x0.70.70.70.70.8 
Inventory Days Days88777 
Debtors Days Days2427243236 
Net fixed assets Rs m2,0952,5982,7583,0032,947 
Share capital Rs m917917917917917 
"Free" reserves Rs m440577676793955 
Net worth Rs m1,3571,4931,5931,7101,871 
Long term debt Rs m44427279297258 
Total assets Rs m3,0023,5814,0204,3814,488 
Interest coverage x13.111.27.86.36.7 
Debt to equity ratio x00.30.20.20.1 
Sales to assets ratio x1.41.21.31.31.5 
Return on assets %11.69.88.28.510.0 
Return on equity %22.920.617.016.818.9 
Return on capital %36.025.824.527.029.9 
Exports to sales %00000 
Imports to sales %2.97.12.84.01.8 
Exports (fob) Rs m00000 
Imports (cif) Rs m122308140238116 
Fx inflow Rs m4015477367031,116 
Fx outflow Rs m141344197319218 
Net fx Rs m260203539384898 
INDRAPRASTHA MEDICAL CASH FLOW
From Operations Rs m 730 334 555 669 581 
From Investments Rs m -361 -573 -280 -540 -218 
From Financial Activity Rs m -357 219 -268 -126 -361 
Net Cashflow Rs m 13 -20 7 3 2 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 49.4%
Foreign collaborators 1.6%
Indian inst/Mut Fund 1.3%
FIIs 0.5%
ADR/GDR 0.0%
Free float 47.2%
Shareholders 38,169
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF Sarita Vihar, Delhi - Mathura Road, New Delhi - 110 076
E-MAIL asinghal@apollohospitals.com WEB www.apollohospdelhi.com
TELEPHONE (011) 2692 5858 FAX (011) 2682 5601
SECTOR HEALTH SERVICES GROUP MISCELLANEOUS
TR AGENT Link Intime India, 44, 2nd Flr., Naraina Indl. Area, Phase I, New Delhi-28
AUDITOR S. C. Vasudeva & Co.
CHM: S. K. Srivastava COMP SEC: A. K. Singhal YEAR OF INC: 1900 BSE CODE: 532150 FV (Rs): 10 DIV YIELD (%): 3.3

More Health Services Company Fact Sheets:   PIRAMAL ENTERPRISES  NOVARTIS  FRESENIUS KABI ONCO.  STRIDES SHASUN LTD  NATCO PHARMA  

Compare INDRAPRASTHA MEDICAL With:   PIRAMAL ENTERPRISES  NOVARTIS  FRESENIUS KABI ONCO.  STRIDES SHASUN LTD  NATCO PHARMA  

Compare INDRAPRASTHA MEDICAL With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Mr Modi Providing Impetus to Defense Industry and Key Stocks in Action Today(Pre-Open)

Addressing the Uttar Pradesh Investors Summit, Mr. Modi announced the creation of a defense industrial corridor in Bundelkhand.

Views on news

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK INDRAPRASTHA MEDICAL

  • Track your investment in INDRAPRASTHA MEDICAL with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDRAPRASTHA MEDICAL

INDRAPRASTHA MEDICAL 8-QTR ANALYSIS

COMPARE INDRAPRASTHA MEDICAL WITH

MARKET STATS